Filsuvez

DRUG2 trials

Sponsors

Amryt Pharma, Stanford University

Conditions

Epidermolysis Bullosa SimplexEpidermolysis Bullosa, DystrophicEpidermolysis Bullosa, Junctional

Phase 2

Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex

Not yet recruitingNCT07756138

Stanford UniversityEpidermolysis Bullosa Simplex

Start: 2026-10-01End: 2028-06-18Target: 10Updated: 2026-08-10

Unknown Phase

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

RecruitingNCT06423573

Amryt PharmaEpidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional

Start: 2024-12-18End: 2032-08-01Target: 580Updated: 2025-09-19